RaQualia Pharma Inc.
Tokyo Stock ExchangeTotal Valuation
RaQualia Pharma Inc. carries a market capitalization of 11.84B, placing it among publicly traded companies globally. Its enterprise value stands at 13.35B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 11.84B |
| Enterprise Value | 13.35B |
Share Statistics
RaQualia Pharma Inc. currently has 21.64M shares outstanding.
| Shares Outstanding | 21.64M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
RaQualia Pharma Inc. trades at a trailing price-to-earnings ratio of 28.92. The price-to-sales ratio is 5.59, and the price-to-book ratio stands at 4.59.
| PE Ratio | 28.92 |
| PS Ratio | 5.59 |
| PB Ratio | 4.59 |
| P/TBV Ratio | 7.95 |
| P/FCF Ratio | -2,182.16 |
| P/OCF Ratio | -96.85 |
Enterprise Valuation
| EV / Sales | 5.81 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 843.92 |
Financial Position
RaQualia Pharma Inc. maintains a current ratio of 3.69, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 65.90, indicating elevated leverage, while an interest coverage ratio of -24.01 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.69 |
| Quick Ratio | 2.56 |
| Debt / Equity | 65.90 |
| Debt / EBITDA | -7.95 |
| Interest Coverage | -24.01 |
Financial Efficiency
| Return on Equity (ROE) | -21.50 |
| Return on Assets (ROA) | -7.77 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.82 |
Taxes
| Income Tax | 68.50M |
| Effective Tax Rate | N/A |
Stock Price Statistics
RaQualia Pharma Inc.'s stock has declined approximately -8.15939% over the past 52 weeks. The 50-day moving average sits at 586.66, while the 200-day moving average is 784.84.
| Beta (5Y) | N/A |
| 52-Week Price Change | -8.15939% |
| 50-Day Moving Average | 586.66 |
| 200-Day Moving Average | 784.84 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, RaQualia Pharma Inc. generated 2.30B in revenue and converted that into -673.00M in net income, yielding earnings per share of -31.12. EBITDA reached -468.20M, while operating income came in at -468.20M.
| Revenue | 2.30B |
| Gross Profit | 1.95B |
| Operating Income | -468.20M |
| Pretax Income | -604.50M |
| Net Income | -673.00M |
| EBITDA | -468.20M |
| EBIT | -468.20M |
| Earnings Per Share (EPS) | -31.12 |
Balance Sheet
RaQualia Pharma Inc. holds 3.21B in cash and equivalents against 3.72B in total debt, resulting in a net debt position of 239.75M. Total book value stands at 2.80B, with working capital of 3.38B providing operational flexibility.
| Cash & Cash Equivalents | 3.21B |
| Total Debt | 3.72B |
| Net Debt | 239.75M |
| Equity (Book Value) | 2.80B |
| Book Value Per Share | 129.39 |
| Working Capital | 3.38B |
Cash Flow
RaQualia Pharma Inc. produced -132.62M in operating cash flow over the past twelve months. After subtracting -126.74M in capital expenditures, free cash flow totaled -259.36M - equivalent to -11.99 per share.
| Operating Cash Flow | -132.62M |
| Capital Expenditures | -126.74M |
| Free Cash Flow | -259.36M |
| FCF Per Share | -11.99 |
Margins
RaQualia Pharma Inc. operates with a gross margin of 84.78, reflecting its pricing power and cost economics. The operating margin of -20.37 and net profit margin of -29.28 provide insight into operational efficiency.
| Gross Margin | 84.78 |
| Operating Margin | -20.37 |
| Pretax Margin | -26.30 |
| Profit Margin | -29.28 |
| EBITDA Margin | -20.37 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -24.61 |
| FCF Yield | -0.05 |
Scores
RaQualia Pharma Inc. posts an Altman Z-Score of 2.54, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.54 |